Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Kura Oncology, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors named therein valued at approximately $150.0 million (effective 2024-01-24).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional accredited investors named therein
- Value
- approximately $150.0 million
- Effective
- 2024-01-24
Exact text from the filing
On January 24, 2024, Kura Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) (i) an aggregate of 1,376,813 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $17.25 per share, and (ii), in lieu of shares of Common Stock to certain Purchasers, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 7,318,886 shares of Common Stock (the “Warrant Shares”) at a purchase price of $17.2499 per Pre-Funded Warrant (representing the $17.25 per Share purchase price less the exercise price of $0.0001 per Warrant Share).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Kura Oncology, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-01-26).
- Action
- entry
- Counterparty
- the Purchasers
- Effective
- 2024-01-26
Exact text from the filing
On January 26, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company agreed to register for resale the Shares and the Warrant Shares held by the Purchasers (the “Registrable Securities”).
View on SEC.gov